A number of research firms have changed their ratings and price targets for Regulus Therapeutics (NASDAQ: RGLS): 4/17/2016 – Regulus Therapeutics had its “buy” rating reaffirmed by analysts at FBR & Co.. They now have a $30.00 price target on the stock. 4/15/2016 – Regulus Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. […]
